## BMS-502

Cat. No.:	HY-149874	
CAS No.:	2407854-18-4	
Molecular Formula:	$C_{27}H_{22}F_{2}N_{6}O_{3}$	
Molecular Weight:	516.5	Ň Ň Ö
Target:	DGK	
Pathway:	Metabolic Enzyme/Protease	
Storage:	-20°C, sealed storage, away from moisture	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	F

## SOLVENT & SOLUBILITY

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9361 mL	9.6805 mL	19.3611 mL
	5 mM	0.3872 mL	1.9361 mL	3.8722 mL
	10 mM	0.1936 mL	0.9681 mL	1.9361 mL

BIOLOGICAL ACTIV	
BIOLOGICALINOIN	
Description	BMS-502 (Compound 22) is a potent dual inhibitor of diacylglycerol kinase (DGK) α and ζ with IC <sub>50</sub> of 4.6 nM and 2.1 nM. BMS- 502 enhanced T cell immune responses in mice. BMS-502 can be used in tumor immunity related research <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC <sub>50</sub> : 4.6 nM (DGK α), 2.1nM (DGK ζ) <sup>[1]</sup> .
In Vitro	BMS-502 has an EC <sub>50</sub> value of 340 nM in the mouse cytotoxic T cell IFN-γ assay (mCTC) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	BMS-502 (Compound 22) (0-10mg/kg; PO; 24h) demonstrates dose-dependent immune stimulation in the mouse OT-1 model <sup>[1]</sup> . Pharmacokinetic Analysis in C57 black mice Model <sup>[1]</sup>
	$\begin{array}{ccc} \text{Route} & \begin{array}{c} \text{Dose} & \text{AUC}_{\text{last}}\left(\mu \right. \\ (\text{mg/kg}) & \text{M-h} \end{array} & \begin{array}{c} t_{1/2}\left(h\right) & T_{\text{max}}\left(h\right) & C_{\text{max}}\left(\mu\text{M}\right) & \begin{array}{c} \text{Cl} \\ (\text{m/min/kg}) \end{array} & \text{V}_{\text{ss}}\left(\text{mL/kg}\right) & \text{F}\left(\%\right) \end{array}$



## Product Data Sheet

1	1	14.8	22.5	/	/	1.9	3.9			
p.o.	5	48	/	3.0	1.08	/	/			
Animal Model	:	OT-1 mou	se model <sup>[1]</sup>							
Dosage:		0-10 mg/kg								
	n.	Oral admi	nistration; 24	h						
Administratio						Result: Caused no significant increase in activated effector T-cells.				

## REFERENCES

[1]. Chupak L, et al. Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization. ACS Med Chem Lett. 2023 Jun 12;14(7):929-935.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA